Skip to main content

Table 4 Outcomes of older patients with acute myeloid leukemia assigned to the genetic groups

From: A precision medicine classification for treatment of acute myeloid leukemia in older patients

Outcome CBF
n = 74
NPM1m/FLT3-ITD-
n = 107
KMT2A
n = 13
IDH2m
n = 59
IDH1m
n = 35
TP53m
n = 50
Complex
karyotype/ TP53wt
n = 28
FLT3m
n = 99
TET2m or WT1m
n = 42
Marker-negative
n = 56
CR 55 (74) 73 (68) 8 (62) 24 (41) 14 (40) 8 (16) 9 (32) 47 (47) 16 (38) 22 (39)
Early death, n (%) 0 (0) 21 (20) 3 (23) 11 (19) 8 (23) 21 (42) 5 (18) 23 (23) 7 (17) 11 (20)
Death in CR, n (%) 6 (11) 4 (5) 3 (38) 1 (4) 1 (7) 0 (0) 0 (0) 9 (19) 0 (0) 1 (5)
Relapse rate, n (%) 34 (62) 59 (81) 5 (63) 23 (96) 13 (93) 8 (100) 9 (100) 37 (79) 16 (100) 18 (82)
Number expired, n (%) 56 (76) 95 (89) 13 (100) 59 (100) 35 (100) 50 (100) 28 (100) 97 (98) 42 (100) 52 (93)
Disease-free survival (DFS)
 Median (years) (95% CI) 0.9 (0.7–1.9) 1.0 (0.8–1.2) 0.5 (0.1–0.7) 0.9 (0.4–1.8) 0.6 (0.3–1.2) 0.4 (0.2–0.4) 0.4 (0.1–0.5) 0.5 (0.3–0.6) 0.7 (0.5–0.9) 0.7 (0.4–1.0)
 % Disease-free at 1 y (95% CI) 48 (35–61) 53 (41–64) 13 (1–42) 46 (26–64) 29 (9–52) 0 11 (1–39) 15 (7–27) 13 (2–33) 41 (21–60)
 % Disease-free at 3 y (95% CI) 30 (18–42) 27 (18–38) 0 8 (1–23) 0 0 0 7 (2–16) 0 14 (3–31)
 % Disease-free at 5 y (95% CI) 30 (18–42) 22 (13–32) 0 4 (0–18) 0 0 0 7 (2–16) 0 14 (3–31)
Overall survival (OS)
 Median (years) (95% CI) 1.5 (1.0–2.0) 1.3 (1.0–1.5) 0.5 (0–0.8) 0.6 (0.4–0.9) 0.6 (0.2–0.8) 0.2 (0.1–0.3) 0.2 (0.1–0.5) 0.5 (0.4–0.6) 0.6 (0.4–0.9) 0.7 (0.3–1.1)
 % Alive at 1 y (95% CI) 61 (48–71) 59 (49–68) 8 (0–29) 36 (24–48) 23 (11–38) 0 21 (9–38) 18 (11–26) 31 (18–45) 39 (27–52)
 % Alive at 3 y (95% CI) 33 (23–44) 27 (19–36) 0 15 (8–26) 6 (1–17) 0 7 (1–20) 7 (3–13) 0 9 (3–18)
 % Alive at 5 y (95% CI) 30 (20–41) 21 (14–29) 0 8 (3–17) 3 (0–13) 0 0 5 (2–11) 0 7 (2–16)
  1. CBF, core-binding factor; CR, complete remission, m, mutated; n, number; y, year; wt, wild-type